EAU 2018

EAU 2018: Game Changer Prostate Evaluation for Clinically Important Disease: Sampling Using Image-Guidance Or Not? - The PRECISION Study

Copenhagen, Denmark (UroToday.com) The accepted standard of care for men with elevated PSA or a suspicious digital rectal examination (DRE) is to undergo a standard transrectal ultrasonography (TRUS) guided systematic prostate biopsy with 10-12 cores. Unfortunately, the rate of under-detection of high grade prostate cancer (PC), or over-detection of low grade insignificant PC is not meager.[1] Randomized trials (PIVOT and PROTECT) have demonstrated no benefit from treatment in men with clinically insignificant cancers.[2, 3]

EAU 2018: Wives of Many Prostate Cancer Sufferers Made Ill or Feel Undermined by the Disease

Truckee, CA (UroToday.com) Many wives of advanced prostate cancer sufferers feel that their lives are being undermined by their husband’s illness, with nearly half reporting that their own health suffered. In addition a focus subgroup has revealed that many feel isolated and fearful, and worry about the role change in their lives as their husband’s cancer advances. This study, developed with the wives of men with metastatic prostate cancer who were being treated with hormone therapy, is amongst the first carried out on how prostate cancer affects the partners of sufferers.  It was presented at the EAU conference in Copenhagen.

EAU 2018: Low Dose Gemcitabine Increases the Cytotoxicity of Human γδT Cell in In Vitro and in an Orthotopic Xenograft Model in Bladder Cancer

Copenhagen, Denmark (UroToday.com) There has long been an effort to identify an effective salvage therapy for NMIBC patients who fail intravesical BCG. Unfortunately, at this time, radical cystectomy remains the best option for these patients. Many agents have been tested and failed to demonstrate significant benefit. However, many newer agents, including immunotherapy agents, are currently in clinical trial. The advantages of an effective BCG salvage are obvious – avoiding cystectomy is an important goal for many patients and physicians, due to the significant impact on patients QOL.

EAU 2018: Influence of Diabetes on the Risk of Urothelial Cancer According to Body Mass Index: A 10-Year Nationwide Population-Based Observational Study

Copenhagen, Denmark (UroToday.com) Obesity and diabetes, and their associated sequelae, have been associated with increase rates of malignancy and worse oncologic outcomes in many different settings. While not always a causal relationship, the association is important. 

EAU 2018: Prostate Cancer Bi-Parametric Versus Multi-Parametric Magnetic Resonance Imaging

Copenhagen, Denmark (UroToday.com) Dr. Barentsz presented an overview of the roles of different modalities encompassed within multiparametric MRI (mpMRI) prostate imaging. Three types of images are usually obtained when imaging the prostate, which help to grade lesions via the PIRADS system. T2 images are good at demonstrating anatomy. Diffusion-weighted images (DWI) are good for demonstrating biology within the tissues. Dynamic contrast enhanced images (DCE) show the vascularity within the tissues. 

EAU 2018: Patient-Reported Outcome Measures in Men with Non-Metastatic Castration-Resistant Prostate Cancer: Baseline Data from the PROSPER Trial

Copenhagen, Denmark (UroToday.com) At GU ASCO 2018, Dr. Maha Hussain presented the data from the PROSPER study, which was an incredibly important study looking at the role for enzalutamide (ENZA) in the setting of non-metastatic castration-resistant prostate cancer (nmCRPC). There was a 71% risk reduction of metastases; MFS was 36.6 months in the ENZA arm compared to just 14.7 months in the placebo arm.

EAU 2018: New Molecular Tumor Markers for Germ Cell Tumors - Ready for Prime Time?

Copenhagen, Denmark (UroToday.com) Testis cancer has been one of few cancers (Prostate (PSA), Colon Cancer (CEA), Ovarian Cancer (CA19-9)) where serum biomarkers play a significant role in staging and in the assessment of treatment response. Unfortunately, the current biomarkers (AFP, HCG, and LDH) are only elevated in ~ 50% of cases and tend to be of minimal value in patients presenting with low stage disease. To date, we are in dire need for tumor-specific biomarkers that allow for better risk stratify patients, especially those with stage I disease, where overtreatment is a significant concern. Dr. Deickmann, from Hamburg, presents data on a novel microRNA based biomarker that is showing remarkable promise to become a testis cancer-specific biomarker.